BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:44 PM
Sep 11, 2012
 |  BC Extra  |  Company News

FDA reviewer gives mixed recommendation on lixivaptan

An FDA reviewer recommended approval of lixivaptan from Cornerstone Therapeutics Inc. (NASDAQ:CRTX) for one of two proposed indications that will be discussed at Thursday's meeting of the Cardiovascular and Renal Drugs Advisory Committee. In briefing documents released Tuesday, the reviewer said "an argument can be made" for approval of...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >